- Conditions
- Parapsoriasis
- Interventions
- Bexarotene 1% gel
- Drug
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2001 – 2004
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 457–480
of 2,629
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Nasal Type Extranodal NK/T-cell Lymphoma, Aplastic Anemia, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Myelodysplastic Syndromes, Chronic Eosinophilic Leukemia, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, Essential Thrombocythemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Juvenile Myelomonocytic Leukemia, Mastocytosis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Nodal Marginal Zone B-cell Lymphoma, Polycythemia Vera, Previously Treated Myelodysplastic Syndromes, Primary Myelofibrosis, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Anemia, Refractory Anemia With Ringed Sideroblasts, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Secondary Myelodysplastic Syndromes, Splenic Marginal Zone Lymphoma, T-cell Large Granular Lymphocyte Leukemia, Waldenström Macroglobulinemia
- Interventions
- Fludarabine, Busulfan, Total Body Irradiation (TBI), Donor Lymphocyte Infusion (DLI), Cyclophosphamide (CY), Tacrolimus, Mycophenolate mofetil, Allogeneic hematopoietic stem cell transplantation, Peripheral blood stem cell transplantation (PBSCT)
- Drug · Radiation · Biological + 2 more
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2022
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Conjunctivitis, Bacterial
- Interventions
- BOL-303224-A
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- High Point, North Carolina
- Conditions
- Cutaneous T-Cell Lymphoma/Mycosis Fungoides
- Interventions
- Hypericin
- Drug
- Lead sponsor
- Soligenix
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Fairport, New York
- Conditions
- Onychomycosis
- Interventions
- Erchonia FX-405™ Laser
- Device
- Lead sponsor
- Erchonia Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Mesa, Arizona
- Conditions
- Tinea Capitis
- Interventions
- Scalp Brushing
- Procedure
- Lead sponsor
- Children's Mercy Hospital Kansas City
- Other
- Eligibility
- 2 Years to 5 Years
- Enrollment
- 446 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2005
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
- Conditions
- Cutaneous T-cell Lymphoma, Cutaneous T-cell Lymphoma Stage I, Mycosis Fungoides, Folliculotropic Mycosis Fungoides, Granulomatous Slack Skin, Syringotropic Mycosis Fungoides, Mycosis Fungoides Variant, Transformed Mycosis Fungoides
- Interventions
- Triamcinolone, Valchlor 0.016 % Topical Gel
- Drug
- Lead sponsor
- Rochester Skin Lymphoma Medical Group, PLLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Fairport, New York
- Conditions
- Refractory Cutaneous T-cell Lymphoma
- Interventions
- Bexarotene
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Miami, Florida • Atlanta, Georgia + 14 more
- Conditions
- Bacterial Disease Carrier, Cystic Fibrosis
- Interventions
- Placebo, WRAIR-PAM-CF1
- Other · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 19
- States / cities
- Tucson, Arizona • La Jolla, California • Los Angeles, California + 15 more
- Conditions
- Aspergillosis, Candidemia
- Interventions
- anidulafungin and voriconazole
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Hartford, Connecticut
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Ritlecitinib, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 30
- States / cities
- Hot Springs, Arkansas • Fountain Valley, California • Northridge, California + 22 more
- Conditions
- HIV, Gonorrhea, Chlamydia
- Interventions
- Keep It Up!, HIV Knowledge Control
- Behavioral
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 29 Years · Male only
- Enrollment
- 901 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2017
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Chicago, Illinois • New York, New York
- Conditions
- Anthrax
- Interventions
- AVP-21D9, Placebo
- Drug
- Lead sponsor
- Emergent BioSolutions
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Meningitis, Meningococcal Infection
- Interventions
- Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate: Menactra®
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 15 Years to 55 Years
- Enrollment
- 834 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 15
- States / cities
- Little Rock, Arkansas • San Diego, California • Bardstown, Kentucky + 12 more
- Conditions
- Lymphoma
- Interventions
- TSEBT
- Radiation
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Clostridioides Difficile Infection
- Interventions
- SER-109
- Biological
- Lead sponsor
- Seres Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 263 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 97
- States / cities
- Dothan, Alabama • Sun City West, Arizona • Mather, California + 84 more
- Conditions
- Inflammation, Vaccine, Intestinal Permeability, Typhoid Fever
- Interventions
- Inulin, Maltodextrin, Ty21a Typhoid Fever Vaccine
- Dietary Supplement · Biological
- Lead sponsor
- USDA, Western Human Nutrition Research Center
- Federal
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Davis, California
- Conditions
- Recurrent Clostridium Difficile Infection, Clostridium Difficile Infection, CDI, C.Difficile Diarrhea, C. Diff Colitis, C.Difficile Colitis
- Interventions
- Vancomycin, Placebo
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 2
- States / cities
- Madison, Wisconsin • Milwaukee, Wisconsin
- Conditions
- Cutaneous T Cell Lymphoma, Fungoides Mycosis Sezary Syndrome
- Interventions
- Pembrolizumab, Mogamulizumab
- Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Nontuberculous Mycobacterial Disease, Atypical Mycobacterium Infections
- Interventions
- Not listed
- Lead sponsor
- University of Illinois Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Fungal Infections, Primary Immune Deficiencies
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 850 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2011
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Onychomycosis
- Interventions
- Albaconazole 100mg, Albaconazole 200mg, Albaconazole 400mg, Placebo 400 mg
- Drug
- Lead sponsor
- Stiefel, a GSK Company
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 582 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Beverly Hills, California + 25 more
- Conditions
- Staphylococcal Aureus Infection, Microbial Colonization, Pediatric Infection, S. Aureus Colonization, Microbial Transplant
- Interventions
- Nasal Microbiota Transplant (NMT), Placebo
- Biological
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 0 Years to 60 Years
- Enrollment
- 175 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Post-Treatment Lyme Disease
- Interventions
- Tetracycline 500 Mg, Placebo
- Drug · Other
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Lutherville, Maryland